Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Neoplasms 2Primary Myelofibrosis 1Pancreatic Neoplasms 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × simtuzumab × Clear all
NCT01369498 2020-07-01

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Gilead Sciences

Phase 2 Completed
54 enrolled 16 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Primary Myelofibrosis

NCT01472198 2015-03-10

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Gilead Sciences

Phase 2 Completed
250 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01323933 2012-05-03

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

Gilead Sciences

Phase 1 Completed
32 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡